| abstract |
A dengue virus glycoprotein comprising (a) a targeting moiety; (b) the sequence DRGWGNGCGLFGKGGI (SEQ ID NO: 1) or a sequence showing 1 to 8 substitutions, deletions or insertions compared to SEQ ID NO: 1 Described is a construct comprising a membrane fusion portion consisting of one or more membrane fusion sequences from E; and (c) a molecule to be delivered to the cytoplasm of a cell. Further described is a pharmaceutical composition comprising a construct according to the invention and optionally a pharmaceutically acceptable carrier. Further, one or more derived from dengue virus glycoprotein E, comprising the sequence shown in SEQ ID NO: 1 or a sequence showing 1-8 substitutions, deletions or insertions compared to SEQ ID NO: 1 A kit comprising the membrane fusion sequence of is described. In addition, dengue virus glycoprotein E for use in the delivery of therapeutic moieties, detectable moieties, nucleic acid molecules, preferably siRNA, carrier molecules, preferably nanoparticles, liposomes, and viral vectors to the cytoplasm of cells. Describes the use of one or more derived membrane fusion sequences. |